Trials / Terminated
TerminatedNCT05388279
A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors
A Phase I Clinical Study Evaluating the Safety ,Tolerability, Pharmacokinetics of JS012 in Patients With Advanced or Metastatic Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd. · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this phase I clinical study was to evaluate the safety and tolerability of JS012 monotherapy and combination with chemotherapy in patients with Advanced or Metastatic Solid Tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JS012 | JS012, i.v., q3w |
| COMBINATION_PRODUCT | JS012 combine with chemotherapy | JS012 i.v., q3w combine with chemotherapy |
Timeline
- Start date
- 2022-04-28
- Primary completion
- 2022-09-19
- Completion
- 2022-09-19
- First posted
- 2022-05-24
- Last updated
- 2023-03-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05388279. Inclusion in this directory is not an endorsement.